For HNSCC, most studies exploring combination therapies that include CTLA-4 inhibitors incorporate conventional treatment options, such as radiotherapy or the inhibition of the PD-1/PD-L1 axis. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.